Category: isoquinoline

On January 29, 2004, Yamada, Rintaro; Seto, Minoru published a patent.Safety of 4-Bromo-5-nitroisoquinoline The title of the patent was Preparation of 5-substituted isoquinoline derivatives as myosin regulatory light-chain phosphorylation inhibitors. And the patent contained the following:

The title compounds I [wherein R1 = H, halo, OH, NH2, or alkoxy; R2 = H, halo, alkenyl, alkynyl, alkoxy,alkylthio, alkyl-SO, alkylsulfonyl, CN, (un)substituted alkyl, amino, etc.; R3 = (un)substituted OH, SO2NH2, or NH2] or salts thereof are prepared as myosin regulatory light-chain phosphorylation inhibitors. For example, N-(tert-butoxycarbonyl)-1,3-propanediamine was reacted with isoquinoline-5-sulfonyl chloride in CH2Cl2 in the presence of NEt3 to give the sulfonamide. The sulfonamide was reacted with 3-phenyl-1-propanol in THF in the presence of 1,1′-azobis(N,N-dimethylformamide) and Bu3P, followed by hydrolysis to provide II•xHCl. II showed inhibitory activity with IC50 of 0.8 μM against human myosin regulatory light-chain phosphorylation. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Safety of 4-Bromo-5-nitroisoquinoline

The Article related to isoquinoline myosin regulatory light chain phosphorylation inhibitor preparation human, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Safety of 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

In, Jinkyung; Hwang, Soonho; Kim, Changhun; Seo, Jae Hong; Kim, Sanghee published an article in 2013, the title of the article was Synthesis of 3,4-Dihydroisoquinolin-1-ones from N-Boc-(β-Arylethyl)carbamates via Isocyanate Intermediates.Safety of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one And the article contains the following content:

Mild reaction conditions for the regioselective synthesis of isoquinolin-1-ones and related fused-ring heterocycles from N-Boc-protected (β-arylethyl)carbamates are described. The reactions involved the use of Tf2O and 2-chloropyridine and isocyanates are likely to be key intermediates. The method was extended to substrates bearing less nucleophilic aryl moieties by using Lewis acid additives, such as BF3·Et2O, to enhance the Friedel-Crafts-type cyclization of the isocyanate intermediates. This method allowed the synthesis of various substituted isoquinolin-1-ones, β-carbolines, thiophene-fused ring systems and tetrahydrobenzoazepin-1-ones in good yields and with high regioselectivities. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Safety of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

The Article related to dihydroisoquinolinone synthesis arylethylcarbamate isocyanate intermediate cyclization, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Safety of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On August 8, 2001, Peglion, Jean-louis; Dessinges, Aimee; Poitevin, Christophe; Vilaine, Jean-paul; Villeneuve, Nicole; Thollon, Catherine; Bourguignon, Marie-pierre published a patent.Formula: C9H5BrN2O2 The title of the patent was Preparation of N-piperidinyl(alkyl)isoquinolinesulfonamides and analogs for treatment of vascular disease. And the patent contained the following:

RSO2NR1Z1ZZ2R2 [I; R = (un)substituted (hetero)aryl; R1 = H or alkyl; R2 = (un)substituted 2- or 3-indenyl or -benzofuranyl; Z = (4-hydroxy)piperidine-4,1-diyl; Z1 = bond or alkylene; Z2 = (un)substituted alk(en)ylene] were prepared Thus, Et 4-piperidinecarboxylate was converted in 5 steps to title compound II. Data for biol. activity of 1 prepared I were given. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Formula: C9H5BrN2O2

The Article related to piperidinylalkylisoquinolinesulfonamide preparation vascular disease treatment, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Formula: C9H5BrN2O2

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On October 31, 1978, Hamada, Yoshiki; Sugiura, Michiharu; Hirota, Minoru published an article.Related Products of 58142-46-4 The title of the article was Studies on nitrogen-containing heterocyclic compounds. XXXIII. Syntheses of 3-alkoxyisoquinolines and 7-,8-substituted-1,6-naphthyridines from isoquinoline and 1,6-naphthyridine. And the article contained the following:

1,3-Dialkoxy-4-bromo-2-cyano-1,2,3,4-tetrahydroisoquinolines are obtained quant. by the addition of BrCN to isoquinoline dissolved in the corresponding alc., followed by application of Br and saturated sodium carbonate solution These products are a mixture of stereoisomers with the H atoms in 3- and 4-positions in cis (main) and trans configuration. Dehydrobromination of the cis-type compounds with KCN easily gives 3-alkoxyisoquinolines. Hydrolysis with HCl affords 4-bromoisoquinoline from cis-type compounds and 4-chloroisoqinoline from trans-type compounds 4-Bromo-5-nitroisoquinoline was obtained from 5-nitroisoquinoline by the application of the above reaction but 3-methoxy-5-nitroisoquinoline could not be obtained. Application of this reaction to 1,6-naphthyridine easily gave 8-bromo-1,6-naphthyridine and 7-methoxy-1,6-naphthyridine. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Related Products of 58142-46-4

The Article related to isoquinoline alkoxy, naphthyridine methoxy, cyanoisoquinoline alkoxy, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Related Products of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On June 6, 2013, Aebi, Johannes; Amrein, Kurt; Chen, Wenming; Hornsperger, Benoit; Kuhn, Bernd; Liu, Yongfu; Maerki, Hans P.; Mayweg, Alexander V.; Mohr, Peter; Tan, Xuefei; Wang, Zhanguo; Zhou, Mingwei published a patent.Application of 58142-46-4 The title of the patent was New bicyclic dihydroisoquinolin-1-one derivatives as aldosterone synthase inhibitors and their preparation. And the patent contained the following:

The invention provides compounds having formula I, compositions including the compounds and methods of using the compounds as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome. Compounds of formula I wherein E is absent and CR3R4; A1 is CR8 and N; A2 is CR9 and N; A3 is CR10 and N; A4 is CR11 and N; A5 is CR6 and N; R1, R2, R3 and R4 are independently H, alkyl, cycloalkyl, haloalkyl, etc.; R2R4 can be taken together to form a double bond, then R5 is H; R1R2, R3R4 or R1R3 can be taken together to form substituted cycloalkyl and heterocycloalkyl; R5, R6, R7 and R8 are independently halo, CN, alkoxy, hydroxyalkoxy, etc.; R9 is H, halo, OH, CN, alkyl, etc.; R10 is (un)substituted alkoxy and substituted alkyl; R11 is H; and with proviso; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by N-arylation of 6-chloro-3,4-dihydroisoquinolin-1(2H)-one with 3-bromopyridine. The invention compounds were evaluated for their aldosterone synthase inhibitory activity. From the assay, it was determined that compound II exhibited EC50 values of 0.0860 μM and 4.6072 μM towards CYP11B2 and CYP11B1, resp. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Application of 58142-46-4

The Article related to dihydroisoquinolinone preparation aldosterone synthase inhibitor, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Application of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On August 20, 2020, Lee, Matthew Randolph; Varano Jr., Anthony Joseph; Bobinski, Thomas P. published a patent.SDS of cas: 58142-46-4 The title of the patent was Sulfonylisoquinolinone derivatives as ROCK kinase inhibitors and their preparation. And the patent contained the following:

The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention. Example compound I was prepared by sulfonylation of 1-chloroisoquinoline with chlorosulfonic acid; the resulting 1-chloroisoquinoline-5-sulfonyl chloride underwent hydrolysis to give 1-hydroxyisoquinoline-5-sulfonic acid, which underwent chlorination to give the corresponding sulfonyl chloride, which underwent amidation with 4-methylisoindoline to give compound I. The invention compounds were evaluated for their ROCK kinase inhibitory activity. From the assay, it was determined that compound I exhibited IC50 value in the range of 1,000 nM to ≤ 10,000 nM. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).SDS of cas: 58142-46-4

The Article related to sulfonylisoquinolinone preparation rock kinase inhibitor, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.SDS of cas: 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On May 14, 2021, Lee, Matthew Randolph; Varano, Anthony Joseph; Bobinski, Thomas P. published a patent.Safety of 4-Bromo-5-nitroisoquinoline The title of the patent was Sulfonylisoquinolinone derivatives as ROCK kinase inhibitors and their preparation. And the patent contained the following:

The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention. Example compound I was prepared by sulfonylation of 1-chloroisoquinoline with chlorosulfonic acid; the resulting 1-chloroisoquinoline-5-sulfonyl chloride underwent hydrolysis to give 1-hydroxyisoquinoline-5-sulfonic acid, which underwent chlorination to give the corresponding sulfonyl chloride, which underwent amidation with 4-methylisoindoline to give compound I. The invention compounds were evaluated for their ROCK kinase inhibitory activity. From the assay, it was determined that compound I exhibited IC50 value in the range of 1,000 nM to ≤ 10,000 nM. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Safety of 4-Bromo-5-nitroisoquinoline

The Article related to sulfonylisoquinolinone preparation rock kinase inhibitor, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Safety of 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On May 7, 2020, Lee, Matthew Randolph; Varano, Anthony Joseph, Jr. published a patent.Product Details of 58142-46-4 The title of the patent was Sulfonylisoquinolinone derivatives as ROCK kinase inhibitors and their preparation. And the patent contained the following:

The invention relates to compounds of formulas I and II that inhibit ROCK activity. The invention relates to compounds of formulas I and II, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the invention. Compounds of formulas I and II wherein ring X is partially saturated aza-containing heteroaryl; Y is CH and N; m is 0, 1, 2 and 3; each R1 is independently CN, OH, hydroxyalkyl, halo, etc.; R2 is H and halo; R3 is H, halo and C1-3 alkyl; and with provisions; and pharmaceutically acceptable salts thereof, are claimed. Example compound III was prepared by sulfonylation of 1-chloroisoquinoline with chlorosulfonic acid; the resulting 1-chloroisoquinoline-5-sulfonyl chloride underwent hydrolysis to give 1-hydroxyisoquinoline-5-sulfonic acid, which underwent chlorination to give the corresponding sulfonyl chloride, which underwent amidation with 4-methylisoindoline to give compound III. The invention compounds were evaluated for their ROCK kinase inhibitory activity. From the assay, it was determined that compound III exhibited IC50 value in the range of 1,000 nM to ≤ 10,000 nM. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Product Details of 58142-46-4

The Article related to sulfonylisoquinolinone preparation rock kinase inhibitor, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Product Details of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On March 31, 1980, Umezawa, Bunsuke; Hoshino, Osamu; Sawaki, Shohei; Mori, Kazuhiko published an article.Computed Properties of 74904-29-3 The title of the article was A cyclization of β-arylethylisocyanates to 3,4-dihydroisocarbostyrils. And the article contained the following:

Isocyanates derived from I (R1 = R4 = H, R2R3 = OCH2O, R2 = R3 = MeO, R2 = MeO, R3 = PhCH2O, R2 = PhCH2O, R3 = MeO; R1 = H, R2 = R3 = R4 = MeO; R1 = HO, R2 = MeO, R3 = HO, R4 = PhCH2; R1 = PhCH2, R2 = HO, R3 = MeO, R4 = H) cyclized on treatment with phosphoric acid to give the dihydroisocarbostyrils II. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Computed Properties of 74904-29-3

The Article related to isocarbostyril dihydro, phenethyl isocyanate cyclization, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Computed Properties of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On August 13, 2020, Milan, David J. published a patent.Related Products of 74904-29-3 The title of the patent was Treating long QT syndrome. And the patent contained the following:

This document relates to compounds useful for treating and preventing disorders associated with long QT syndrome such as cardiac arrhythmia, ventricular arrhythmia, hypertrophic cardiomyopathy, and congestive heart failure. Also provided herein are methods and materials for using such compounds to shorten myocardial repolarization time in a patient. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Related Products of 74904-29-3

The Article related to myocardial repolarization long qt syndrome therapy heart failure arrhythmia, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Related Products of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem